Serum Acylcarnitines May Predict Kidney Decline in Diabetes
A recent study found that serum levels of eleven acylcarnitines are linked to the decline in kidney function among patients with type 2 diabetes. The research suggests that these acylcarnitines can enhance the prediction of kidney function decline. The study was led by Vincenzo Trischitta and published in BMJ Open Diabetes Research & Care.
- ▪The study involved a discovery cohort of 575 patients and a validation cohort of 252 patients with type 2 diabetes.
- ▪Eleven acylcarnitines were independently associated with accelerated decline in estimated glomerular filtration rate (eGFR).
- ▪A multimarker score comprising six acylcarnitines improved the prediction of rapid eGFR decline.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/serum-acylcarnitines-may-predict-kidney-decline-diabetes-2026a1000gnh?src=rss |
| Publication time | Fri, 22 May 2026 07:54:33 EDT |
| Retrieval time | 2026-05-22T12:02:01.659Z |
| Last seen | 2026-05-22T12:02:01.659Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | L6N2kHefwSyt |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A prospective study showed that serum levels of eleven acylcarnitines were associated with the rate of decline in estimated glomerular filtration rate (eGFR) among patients with type 2 diabetes (T2D). Furthermore, combining six of these molecules into a score improved clinical risk prediction models for kidney function decline.METHODOLOGY:Although several metabolites have been found to affect the risk for kidney function decline in T2D, the role of circulating acylcarnitines — whose accumulation is considered a potential mechanism in kidney disease — has not been fully explored.Researchers conducted a prospective study to examine the association between baseline levels of 40 serum acylcarnitines and the decline in eGFR (mL/min/1.73 m2) in patients with T2D.They investigated two…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
